This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
ThousandOaks-based Ceres , the developer of specialized seeds for the biofuels market, has priced its IPO, saying that it will offer up 5,000,000 shares of its common stock at $13.00 The firm will start trading today on the NASDAQ Global Market as CERE. The IPO was underwritten by Goldman, Sachs & CO.,
ThousandOaks-based Ceres , the developer of seeds to supply the bioenergy and biofuels feedstock business, has set its initial pricing range for its IPO, according to a filing from the company this morning. Ceres said it now expects its IPO to price at between $21.00 and $23.00
ThousandOaks-based Ceres , which develops specialized seeds for the biofuels industry, is planning to hit the market on February 9th, according to the NASDAQ IPO calendar. Ceres recently estimated its IPO pricing at between $21.00 Ceres has applied to list as CERE on the NASDAQ Global Market. and $23.00
RealD said last night that it had priced its IPO at $16.00, and is selling 12.5M Tags: financing public market acquisition merger reald. With the IPO of Los Angeles-based RealD , which starts trading this morning on the NYSE as RLD, Southern California now has three successful IPOs on record. shares of its common stock.
ThousandOaks-based Teledyne Technologies said this morning that it has acquired a majority interest in Solvang-based Nova Sensors. Teledyne said the move would bolster its involvement in infrared imaging systems for the commercial and tactical military market. Financial terms of the deal were not disclosed. READ MORE>>.
ThousandOaks-based Ceres , the biotechnology firm developing specialized seed stocks for the biofuels industry, rose in its IPO on Wednesday, closing at $14.80 The firm priced its IPO on Tuesday evening at $13.00 per share, pricing lower than expected after a delay in its IPO.
per share, after pricing below its initial offering range on Wednesday evening, and had traded as high as $15.26 The firm's stock was up in its debut despite a down market for the day, with the NASDAQ down -4.11 The firm sold 4,166,667 shares of stock at $13.00 during the day. percent to 2,204.01.
Southern California appears to be on a IPO roll this month, with the pricing of Monrovia-based Green Dot 's IPO last night and expected trading today, following the successful IPO of Beverly Hills-based RealD last Friday.
ThousandOaks-based Xirrus , a developer of Wi-Fi networking equipment, announced Monday that it has put together a portable, pre-packaged kit which is designed for deploying Wi-Fi into disaster response and temporary events. The firm said it would offer the new product online, priced starting at $3,999.
I grew up in ThousandOaks, went to USC, and we met each other way back in the 90's. Those loans are very mis-priced, in our opinion. There's a massive market, and there is no end to the opportunities here to create efficiency and transform things for the better. Brett and I both grew up in Southern California.
Just as many M&A rumors flame out as lead to deals, of course, but the news was enough to give Biogen’s stock price a big bump, and ignite chatter about what a sale of one of biotech’s heavyweights would mean, particularly for the Boston area. The rumors boosted Biogen’s sinking stock price nearly 10 percent.
Unfortunately, those providers decided the gold leads were expensive, and decided to use a Chinese vendor which would provide them at half price. The concept of the incubator is we''re raising a fund here locally and ten percent is local the other 90 percent on AngelList, and we''ll be locating here in the town of ThousandOaks.
BIO president and CEO Jim Greenwood (pictured), a former Congressman-turned-lobbyist, told an audience, “We are fighting back,” and unveiled plans to put some of the blame for high drug prices on insurance companies. The new prices don’t reflect rebates and discounts. The full data set has yet to be released.
Mylan bumped up the price of the EpiPen 400 percent, presidential nominee Hillary Clinton responded with a tirade against drug price hikes, and—much like when Clinton railed against drug pricing last year—biotech indexes promptly plummeted more than 3 percent. It was the tweet heard around the biotech world, again.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content